Rate Video

ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR

Solange Peters • 19 Oct 2018

Lung Cancer Non-Small Cell Lung Cancer Denosumab

Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.

Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC

Solange Peters • 11 Apr 2018

Data update in advanced stage NSCLC

Solange Peters • 6 May 2017

Securing access to optimal cancer care

Solange Peters • 20 Oct 2018

ESMO 2016: From disease treatment to patient care

Solange Peters • 7 Oct 2016

Related Videos

Updates on MRx0518 + pembro in patients with resistance to therapy

Alex Stevenson • 27 Nov 2020

STIMULI trial update at ESMO 2020

Dirk De Ruysscher • 16 Nov 2020

Exciting updates at the Gathering around Cancer meeting

Jarushka Naidoo • 4 Nov 2020

Osimertinib for EGFR-mutant lung cancer

Jarushka Naidoo • 4 Nov 2020